Which field best represents your expertise? *

Primary Care Physician

Dermatologist

Medical Oncologist

Surgeon

RN / Nurse

Research / Laboratory

Medical Student

Post-Doctorate Student

SMR Member

Non-Member

Invited Faculty

Poster Author

Please describe your satisfaction with the following *

	Very Satisfied	Satisfied	Neither satisfied nor dissatisfied	Dissatisfied	Very Dissatisfied
Registration Process (user-friendliness of website, onsite check-in; phone support)	Registration Process (user-friendliness of website, onsite check-in; phone support) - Very Satisfied	Registration Process (user-friendliness of website, onsite check-in; phone support) - Satisfied	Registration Process (user-friendliness of website, onsite check-in; phone support) - Neither satisfied nor dissatisfied	Registration Process (user-friendliness of website, onsite check-in; phone support) - Dissatisfied	Registration Process (user-friendliness of website, onsite check-in; phone support) - Very Dissatisfied
Grand America Hotel (overall comfort and customer service)	Grand America Hotel (overall comfort and customer service) - Very Satisfied	Grand America Hotel (overall comfort and customer service) - Satisfied	Grand America Hotel (overall comfort and customer service) - Neither satisfied nor dissatisfied	Grand America Hotel (overall comfort and customer service) - Dissatisfied	Grand America Hotel (overall comfort and customer service) - Very Dissatisfied
Scientific Program(s) (for any or all of the sessions you attended)	Scientific Program(s) (for any or all of the sessions you attended) - Very Satisfied	Scientific Program(s) (for any or all of the sessions you attended) - Satisfied	Scientific Program(s) (for any or all of the sessions you attended) - Neither satisfied nor dissatisfied	Scientific Program(s) (for any or all of the sessions you attended) - Dissatisfied	Scientific Program(s) (for any or all of the sessions you attended) - Very Dissatisfied
Faculty	Faculty - Very Satisfied	Faculty - Satisfied	Faculty - Neither satisfied nor dissatisfied	Faculty - Dissatisfied	Faculty - Very Dissatisfied
Poster Abstracts (quality of research presented and display time)	Poster Abstracts (quality of research presented and display time) - Very Satisfied	Poster Abstracts (quality of research presented and display time) - Satisfied	Poster Abstracts (quality of research presented and display time) - Neither satisfied nor dissatisfied	Poster Abstracts (quality of research presented and display time) - Dissatisfied	Poster Abstracts (quality of research presented and display time) - Very Dissatisfied
Conference Materials (program booklet, signage, etc.)	Conference Materials (program booklet, signage, etc.) - Very Satisfied	Conference Materials (program booklet, signage, etc.) - Satisfied	Conference Materials (program booklet, signage, etc.) - Neither satisfied nor dissatisfied	Conference Materials (program booklet, signage, etc.) - Dissatisfied	Conference Materials (program booklet, signage, etc.) - Very Dissatisfied
Level of Interaction	Level of Interaction - Very Satisfied	Level of Interaction - Satisfied	Level of Interaction - Neither satisfied nor dissatisfied	Level of Interaction - Dissatisfied	Level of Interaction - Very Dissatisfied

Additional comments

Based on your knowledge prior to the Congress *

	Greatly	Moderately	Neutral	Slightly	None
To what extent have you increased your scientific knowledge as a result of attending the 2019 Society for Melanoma Research International Congress?	To what extent have you increased your scientific knowledge as a result of attending the 2019 Society for Melanoma Research International Congress? - Greatly	To what extent have you increased your scientific knowledge as a result of attending the 2019 Society for Melanoma Research International Congress? - Moderately	To what extent have you increased your scientific knowledge as a result of attending the 2019 Society for Melanoma Research International Congress? - Neutral	To what extent have you increased your scientific knowledge as a result of attending the 2019 Society for Melanoma Research International Congress? - Slightly	To what extent have you increased your scientific knowledge as a result of attending the 2019 Society for Melanoma Research International Congress? - None

As a result of participating in this activity, I am better able to *

	Strongly Agree	Agree	Neutral	Disagree	Strongly Disagree
Discuss the latest research findings on melanoma causation, susceptibility, epidemiology, as well as the importance of prevention and early diagnosis	Discuss the latest research findings on melanoma causation, susceptibility, epidemiology, as well as the importance of prevention and early diagnosis - Strongly Agree	Discuss the latest research findings on melanoma causation, susceptibility, epidemiology, as well as the importance of prevention and early diagnosis - Agree	Discuss the latest research findings on melanoma causation, susceptibility, epidemiology, as well as the importance of prevention and early diagnosis - Neutral	Discuss the latest research findings on melanoma causation, susceptibility, epidemiology, as well as the importance of prevention and early diagnosis - Disagree	Discuss the latest research findings on melanoma causation, susceptibility, epidemiology, as well as the importance of prevention and early diagnosis - Strongly Disagree
Demonstrate an understanding of clinically important breakthroughs in melanoma genetics and genomics, including the emerging role of molecular testing on therapy decisions	Demonstrate an understanding of clinically important breakthroughs in melanoma genetics and genomics, including the emerging role of molecular testing on therapy decisions - Strongly Agree	Demonstrate an understanding of clinically important breakthroughs in melanoma genetics and genomics, including the emerging role of molecular testing on therapy decisions - Agree	Demonstrate an understanding of clinically important breakthroughs in melanoma genetics and genomics, including the emerging role of molecular testing on therapy decisions - Neutral	Demonstrate an understanding of clinically important breakthroughs in melanoma genetics and genomics, including the emerging role of molecular testing on therapy decisions - Disagree	Demonstrate an understanding of clinically important breakthroughs in melanoma genetics and genomics, including the emerging role of molecular testing on therapy decisions - Strongly Disagree
Describe the role of normal and mutated BRAF in intracellular signaling and explain the rationale for BRAF and MEK inhibition in the treatment of melanoma	Describe the role of normal and mutated BRAF in intracellular signaling and explain the rationale for BRAF and MEK inhibition in the treatment of melanoma - Strongly Agree	Describe the role of normal and mutated BRAF in intracellular signaling and explain the rationale for BRAF and MEK inhibition in the treatment of melanoma - Agree	Describe the role of normal and mutated BRAF in intracellular signaling and explain the rationale for BRAF and MEK inhibition in the treatment of melanoma - Neutral	Describe the role of normal and mutated BRAF in intracellular signaling and explain the rationale for BRAF and MEK inhibition in the treatment of melanoma - Disagree	Describe the role of normal and mutated BRAF in intracellular signaling and explain the rationale for BRAF and MEK inhibition in the treatment of melanoma - Strongly Disagree
Assess the impact of new therapies on overall survival in metastatic melanoma	Assess the impact of new therapies on overall survival in metastatic melanoma - Strongly Agree	Assess the impact of new therapies on overall survival in metastatic melanoma - Agree	Assess the impact of new therapies on overall survival in metastatic melanoma - Neutral	Assess the impact of new therapies on overall survival in metastatic melanoma - Disagree	Assess the impact of new therapies on overall survival in metastatic melanoma - Strongly Disagree
Describe the process of T-cell activation and checkpoints to control T-cell activity	Describe the process of T-cell activation and checkpoints to control T-cell activity - Strongly Agree	Describe the process of T-cell activation and checkpoints to control T-cell activity - Agree	Describe the process of T-cell activation and checkpoints to control T-cell activity - Neutral	Describe the process of T-cell activation and checkpoints to control T-cell activity - Disagree	Describe the process of T-cell activation and checkpoints to control T-cell activity - Strongly Disagree
Identify the 4 patterns of response to immunotherapy and apply new immune-related response criteria (irRC)	Identify the 4 patterns of response to immunotherapy and apply new immune-related response criteria (irRC) - Strongly Agree	Identify the 4 patterns of response to immunotherapy and apply new immune-related response criteria (irRC) - Agree	Identify the 4 patterns of response to immunotherapy and apply new immune-related response criteria (irRC) - Neutral	Identify the 4 patterns of response to immunotherapy and apply new immune-related response criteria (irRC) - Disagree	Identify the 4 patterns of response to immunotherapy and apply new immune-related response criteria (irRC) - Strongly Disagree
Monitor for and promptly treat immune-related adverse events (IRAEs) in patients taking newer therapies for metastatic melanoma	Monitor for and promptly treat immune-related adverse events (IRAEs) in patients taking newer therapies for metastatic melanoma - Strongly Agree	Monitor for and promptly treat immune-related adverse events (IRAEs) in patients taking newer therapies for metastatic melanoma - Agree	Monitor for and promptly treat immune-related adverse events (IRAEs) in patients taking newer therapies for metastatic melanoma - Neutral	Monitor for and promptly treat immune-related adverse events (IRAEs) in patients taking newer therapies for metastatic melanoma - Disagree	Monitor for and promptly treat immune-related adverse events (IRAEs) in patients taking newer therapies for metastatic melanoma - Strongly Disagree
Evaluate ongoing investigations of treatments for metastatic melanoma, including optimizing patient selection for clinical trials.	Evaluate ongoing investigations of treatments for metastatic melanoma, including optimizing patient selection for clinical trials. - Strongly Agree	Evaluate ongoing investigations of treatments for metastatic melanoma, including optimizing patient selection for clinical trials. - Agree	Evaluate ongoing investigations of treatments for metastatic melanoma, including optimizing patient selection for clinical trials. - Neutral	Evaluate ongoing investigations of treatments for metastatic melanoma, including optimizing patient selection for clinical trials. - Disagree	Evaluate ongoing investigations of treatments for metastatic melanoma, including optimizing patient selection for clinical trials. - Strongly Disagree

Please rate your level of agreement with the following statements *

	Strongly Agree	Agree	Neutral	Disagree	Strongly Disagree
This activity met my educational needs, expectations, and objectives	This activity met my educational needs, expectations, and objectives - Strongly Agree	This activity met my educational needs, expectations, and objectives - Agree	This activity met my educational needs, expectations, and objectives - Neutral	This activity met my educational needs, expectations, and objectives - Disagree	This activity met my educational needs, expectations, and objectives - Strongly Disagree
This activity was relevant to my practice or profession	This activity was relevant to my practice or profession - Strongly Agree	This activity was relevant to my practice or profession - Agree	This activity was relevant to my practice or profession - Neutral	This activity was relevant to my practice or profession - Disagree	This activity was relevant to my practice or profession - Strongly Disagree
I feel confident treating patients in my practice based on this activity	I feel confident treating patients in my practice based on this activity - Strongly Agree	I feel confident treating patients in my practice based on this activity - Agree	I feel confident treating patients in my practice based on this activity - Neutral	I feel confident treating patients in my practice based on this activity - Disagree	I feel confident treating patients in my practice based on this activity - Strongly Disagree
This activity rates highly in comparison with other CE/CME activities in which I have participated in the last 12 months	This activity rates highly in comparison with other CE/CME activities in which I have participated in the last 12 months - Strongly Agree	This activity rates highly in comparison with other CE/CME activities in which I have participated in the last 12 months - Agree	This activity rates highly in comparison with other CE/CME activities in which I have participated in the last 12 months - Neutral	This activity rates highly in comparison with other CE/CME activities in which I have participated in the last 12 months - Disagree	This activity rates highly in comparison with other CE/CME activities in which I have participated in the last 12 months - Strongly Disagree
There is a continuing need for education on this topic	There is a continuing need for education on this topic - Strongly Agree	There is a continuing need for education on this topic - Agree	There is a continuing need for education on this topic - Neutral	There is a continuing need for education on this topic - Disagree	There is a continuing need for education on this topic - Strongly Disagree
The presentations were scientifically sound and free of commercial bias or influence	The presentations were scientifically sound and free of commercial bias or influence - Strongly Agree	The presentations were scientifically sound and free of commercial bias or influence - Agree	The presentations were scientifically sound and free of commercial bias or influence - Neutral	The presentations were scientifically sound and free of commercial bias or influence - Disagree	The presentations were scientifically sound and free of commercial bias or influence - Strongly Disagree

If you thought the presentations were commercially biased, please explain

Do you plan to attend the International Congress of the Society for Melanoma Research in 2020, or any future SMR Congress? *

Yes

No

Not sure

Would you recommend this conference to any colleagues? *

Yes

No

If yes, please provide their name/email

Approximately how many conferences of this type do you attend annually, other than the Annual SMR Congress? *

1-2

3-4

5-6

>6

None

Are you a member of SMR? *

Yes

No

If no, please indicate why you do not have a membership

Are there topics or faculty members you feel should be involved at future congress'?

For you, was the educational level of this activity *

Too basic

Appropriate

Too advanced

Of all of the patients that you see per month, how many are likely to be impacted by the information that you acquired in this CE/CME activity? (example: 50) *

Based upon your participation in this activity, choose the statements that apply *

I plan to implement new strategies/skills/information

I gained new strategies/skills/information that I can apply to my area of practice

I need more information before I can implement new strategies/skills/information

My current practice is consistent with the information presented

This topic is not within my scope of practice

I do not agree with the information presented

What, if any, additional changes do you plan to implement into your practice?

My confidence level in being able to implement these changes is *

Very confident

Somewhat confident

Uncertain

Little confidence

No confidence

Not applicable

If you consider a change in practice, please check any barriers to overcome before initiating that change *

Organizational constraints

Formulary issues

Patient reluctance to change

Patient nonadherence

Insufficient time

Financial/Insurance

Do not know enough about the recommendations to change yet

What still remains unanswered for you?

Additional comments

Leave this field blank